Cargando…
Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study
Ambroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its effectiveness on coronavirus disease-2019 (COVID...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582747/ https://www.ncbi.nlm.nih.gov/pubmed/36274736 http://dx.doi.org/10.3389/fmicb.2022.1013038 |
_version_ | 1784812911612395520 |
---|---|
author | Lu, Yun Yang, Qing-qing Zhuo, Lin Yang, Kun Kou, Hao Gao, Su-yu Hu, Wen Jiang, Qiao-li Li, Wen-jing Wu, Dong-fang Sun, Feng Cheng, Hong Zhan, Siyan |
author_facet | Lu, Yun Yang, Qing-qing Zhuo, Lin Yang, Kun Kou, Hao Gao, Su-yu Hu, Wen Jiang, Qiao-li Li, Wen-jing Wu, Dong-fang Sun, Feng Cheng, Hong Zhan, Siyan |
author_sort | Lu, Yun |
collection | PubMed |
description | Ambroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its effectiveness on coronavirus disease-2019 (COVID-19) patients. To study the association between ambroxol use and clinical outcomes among hospitalized patients of COVID-19 infection. We conducted a multicenter retrospective cohort study involving 3,111 patients with confirmed SARS-CoV-2 infection from three hospitals in Wuhan from 19 December 2019 to 15 April 2020, and the primary outcome was in-hospital mortality. COVID-19 patients were classified into ambroxol and non-ambroxol groups based on the administration of ambroxol during hospitalization. Two analyses including propensity score matching (PSM) to obtain a 1:1 balanced cohort and logistic regression were used to control for confounding factors. The average age of 3,111 patients was 57.55 ± 14.93 years old, 127 of them died during hospitalization, and 924 of them used ambroxol. Treatment with ambroxol did not have a significant effect on in-hospital mortality of COVID-19 patients when compared with non-ambroxol in PSM model after adjusting for confounders (8.0% vs. 3.5%, adjusted OR, 1.03 [95% CI, 0.54–1.97], p = 0.936). Adverse events such as nausea/vomiting, headache, and rash were comparable between the two groups. Our results suggest that the use of ambroxol is not significantly associated with in-hospital mortality in COVID-19 patients, which provides evidence for evaluating the effects of ambroxol on COVID-19 patient outcomes and may be helpful for physicians considering medication alternatives for COVID-19 patients. |
format | Online Article Text |
id | pubmed-9582747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95827472022-10-21 Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study Lu, Yun Yang, Qing-qing Zhuo, Lin Yang, Kun Kou, Hao Gao, Su-yu Hu, Wen Jiang, Qiao-li Li, Wen-jing Wu, Dong-fang Sun, Feng Cheng, Hong Zhan, Siyan Front Microbiol Microbiology Ambroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its effectiveness on coronavirus disease-2019 (COVID-19) patients. To study the association between ambroxol use and clinical outcomes among hospitalized patients of COVID-19 infection. We conducted a multicenter retrospective cohort study involving 3,111 patients with confirmed SARS-CoV-2 infection from three hospitals in Wuhan from 19 December 2019 to 15 April 2020, and the primary outcome was in-hospital mortality. COVID-19 patients were classified into ambroxol and non-ambroxol groups based on the administration of ambroxol during hospitalization. Two analyses including propensity score matching (PSM) to obtain a 1:1 balanced cohort and logistic regression were used to control for confounding factors. The average age of 3,111 patients was 57.55 ± 14.93 years old, 127 of them died during hospitalization, and 924 of them used ambroxol. Treatment with ambroxol did not have a significant effect on in-hospital mortality of COVID-19 patients when compared with non-ambroxol in PSM model after adjusting for confounders (8.0% vs. 3.5%, adjusted OR, 1.03 [95% CI, 0.54–1.97], p = 0.936). Adverse events such as nausea/vomiting, headache, and rash were comparable between the two groups. Our results suggest that the use of ambroxol is not significantly associated with in-hospital mortality in COVID-19 patients, which provides evidence for evaluating the effects of ambroxol on COVID-19 patient outcomes and may be helpful for physicians considering medication alternatives for COVID-19 patients. Frontiers Media S.A. 2022-10-06 /pmc/articles/PMC9582747/ /pubmed/36274736 http://dx.doi.org/10.3389/fmicb.2022.1013038 Text en Copyright © 2022 Lu, Yang, Zhuo, Yang, Kou, Gao, Hu, Jiang, Li, Wu, Sun, Cheng and Zhan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Lu, Yun Yang, Qing-qing Zhuo, Lin Yang, Kun Kou, Hao Gao, Su-yu Hu, Wen Jiang, Qiao-li Li, Wen-jing Wu, Dong-fang Sun, Feng Cheng, Hong Zhan, Siyan Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study |
title | Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study |
title_full | Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study |
title_fullStr | Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study |
title_full_unstemmed | Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study |
title_short | Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study |
title_sort | ambroxol for the treatment of covid-19 among hospitalized patients: a multicenter retrospective cohort study |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582747/ https://www.ncbi.nlm.nih.gov/pubmed/36274736 http://dx.doi.org/10.3389/fmicb.2022.1013038 |
work_keys_str_mv | AT luyun ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT yangqingqing ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT zhuolin ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT yangkun ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT kouhao ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT gaosuyu ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT huwen ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT jiangqiaoli ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT liwenjing ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT wudongfang ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT sunfeng ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT chenghong ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT zhansiyan ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy |